Abstract: The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-15Ra or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
Type:
Grant
Filed:
January 6, 2014
Date of Patent:
March 8, 2016
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
David B. Weiner, Kimberly A. Kraynyak, Michele Kutzler
Abstract: This invention relates to novel unique strains avian reoviridae that were isolated from severe cases of Runting Stunting Syndrome. The present invention also relates to the isolation and uses of novel unique avian reoviridae, diagnostic assays using nucleotide or amino acid specific components of such viruses, such as the sequence encoding Sigma C capsid protein and to vaccines that protect birds from diseases caused by such viruses.
Type:
Grant
Filed:
June 26, 2009
Date of Patent:
March 1, 2016
Assignee:
BIOMUNE COMPANY
Inventors:
Kristi Mae Dorsey, John Konx Rosenberger, Sandra Cloud Rosenberger
Abstract: Disclosed are fusion proteins, recombinant nucleic acid molecules, and therapeutic compositions, including yeast-based immunotherapy compositions, for use in the diagnosis, prevention and treatment of adenovirus-36 (Ad-36) infection and sequela thereof.
Type:
Grant
Filed:
December 19, 2011
Date of Patent:
February 9, 2016
Assignee:
GlobeImmune, Inc.
Inventors:
David Apelian, Thomas King, Claire Coeshott, Yingnian Lu
Abstract: The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures.
Type:
Grant
Filed:
February 3, 2010
Date of Patent:
February 9, 2016
Inventors:
Samuel Bogoch, Elenore S. Bogoch, Samuel Winston Bogoch, Anne Elenore Borsanyi
Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.
Type:
Grant
Filed:
September 13, 2008
Date of Patent:
January 12, 2016
Assignee:
Biogen MA Inc.
Inventors:
Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3?-monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.
Type:
Grant
Filed:
April 10, 2012
Date of Patent:
October 27, 2015
Assignees:
Institut National de la Santé et de la Recherche Médicale (INSERM), Université Claude Bernard - Lyon 1
Inventors:
Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex
Abstract: A persistently infective virus vector is produced by using a gene so modified as to encode an amino acid sequence including a valine substituted for an amino acid residue at position-1618 in the amino acid sequence for an L protein of a persistently non-infective Sendai virus. A non-transmissible, persistently infective virus vector is also produced by defecting or deleting at least one of M gene, F gene, and HN gene. These virus vectors have no cytotoxicity, can achieve the sustained gene expression over a long period of time, is safe, and is therefore useful.
Type:
Grant
Filed:
April 11, 2008
Date of Patent:
September 29, 2015
Assignee:
National Institute of Advanced Industrial Science and Technology
Inventors:
Ken Nishimura, Hiroaki Segawa, Mahito Nakanishi
Abstract: The present invention pertains to a protein having the characteristics of a serine protease having an amino acid sequence according to SEQ ID NO 2 for use as a medicament. The invention also pertains to this protein for use in a vaccine to protect an animal against an infection with a micro organism that secretes said protein, and to the corresponding antibodies directed against the protein.
Type:
Grant
Filed:
April 20, 2012
Date of Patent:
September 22, 2015
Assignee:
The University Court of the University of Aberdeen
Inventors:
Pieter van West, Christopher John Secombes, Victoria Louise Anderson, Kirsty Louise Minor
Abstract: Described herein are isolated paramyxovirus, a morbillivirus (FmoPV), nucleic acid molecules, polypeptides and antibodies related to FmoPV and uses thereof. In certain embodiments, the FmoPV is a feline morbillivirus. Also described herein is a recombinant FmoPV comprising a modified FmoPV gene or gene segments and uses thereof. Also described is a recombinant FmoPV for the prevention and/or treatment of diseases related to FmoPV or a delivery vector. Also described herein is a diagnostic assay for FmoPV, natural or artificial variants, analogs, or derivatives thereof. Also described herein is a vaccine and a kit containing the vaccine for the prevention and treatment of FmoPV infection. Also provided is a diagnostic kit comprising nucleic acid molecules for the detection of FmoPV.
Type:
Grant
Filed:
January 22, 2013
Date of Patent:
September 22, 2015
Assignees:
THE GOVERNMENT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, VERSITECH LIMITED
Inventors:
Kwok-Yung Yuen, Patrick Chiu-Yat Woo, Susanna Kar-Pui Lau
Abstract: The present invention discloses positive control material for nucleic acid amplification based detection of microorganisms in biological samples. The control material comprises purified microorganism that is rendered non-infectious but is amenable to nucleic acid amplification. Also disclosed is a process for making and using the control material.
Abstract: Novel models of interactions of the Nonstructural Protein of influenza A and influenza B viruses (NS1A and NS1B, respectively) with dsRNA are presented. On the basis of the models, novel recombinant viruses and vaccines against influenza A and influenza B viruses are provided.
Type:
Grant
Filed:
November 17, 2006
Date of Patent:
September 1, 2015
Assignees:
Rutgers, The State University of New Jersey
Inventors:
Gaetano T. Montelione, Robert M. Krug, Yin Cuifeng, Ma Lichung
Abstract: The present invention discloses positive control material for nucleic acid amplification based detection of microorganisms in biological samples. The control material comprises purified microorganism that is rendered non-infectious but is amenable to nucleic acid amplification. Also disclosed is a process for making and using the control material.
Abstract: The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain.
Abstract: An object of the present invention is to provide an HIV antibody-inducing peptide antigen that is effective in developing an antibody or a vaccine having specificity and binding activity for the three-dimensional structure of a neutralization target, i.e. the mechanism by which HIV invades a target cell; a method for synthesizing the same; a vaccine comprising the peptide antigen, or an HIV three-dimensional structure-recognizing antibody induced by the peptide antigen; and a preventive and/or therapeutic agent for HIV infection comprising the peptide antigen, the vaccine, or the HIV three-dimensional structure-recognizing antibody as an active ingredient.
Type:
Grant
Filed:
May 14, 2010
Date of Patent:
June 30, 2015
Assignee:
NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
Abstract: A method of lysing at least one of a cell and a virus, the method including: contacting a sample, which includes at least one of a cell and a virus, with a plurality of beads which are disposed in a first chamber to obtain a combination of the sample and the beads; and agitating the combination of the sample and the beads to lyse the at least one of the cell and the virus, wherein in the first chamber a liquid volume fraction is 0.6 or less, and wherein the liquid volume fraction is a value obtained by dividing a liquid volume of the first chamber by a pure void volume equivalent to a sum of the liquid volume of the first chamber and a void volume of the first chamber.
Type:
Grant
Filed:
October 28, 2011
Date of Patent:
March 24, 2015
Assignee:
Samsung Electronics Co., Ltd.
Inventors:
Kyu-youn Hwang, Joon-ho Kim, Sung-hong Kwon, Chin-sung Park, Hee-kyun Lim, Sun-ok Jung, Won-jong Jung
Abstract: Described are parvovirus variants derived, e.g., from H-1PV, showing higher anti-tumor potential compared to the wild type parvovirus, wherein said variant is characterized by (a) an amino acid substitution, alteration or addition, preferably substitution at position Lys96 of NS-2 and/or position Leu103 of NS-2 (together with a amino acid substitution at position Tyr595 of NS-1 in the latter case), or (b) an in-frame deletion in the parvovirus genome, preferably a deletion resulting in a large amino acid deletion in both the central part (aa 96-133) of NS-2 and the C-terminal part (aa 587-624) of NS-1. The present invention also relates to the use of said parvovirus variants for cancer therapy.
Type:
Grant
Filed:
December 13, 2012
Date of Patent:
December 23, 2014
Assignee:
Deutsches Krebsforschungszentrum
Inventors:
Nathalie Salome, Christiane Dinsart, Nadine Michel, Jean Rommelaere
Abstract: The invention provides engineered antibody domains (eAds), a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the same. Nucleic acids encoding eAd and/or polypeptide or the fusion protein thereof, as well as compositions or cells comprising the eAd, polypeptide, fusion protein, or nucleic acid also are provided.
Type:
Grant
Filed:
May 20, 2011
Date of Patent:
December 16, 2014
Assignee:
The United States of America, as represented by the Secretary of the Department of Health and Human Services